Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.


Latest News

02.02.2016: WILEX AG: US-patent office granted patent for amatoxin conjugates for tumour therapy. WILEX AG today announced that an important patent for its own ADC technology for the manufacture of Antibody Amanitin Conjugates was granted in the USA. ....More




Seite gelesen: 435938 | Heute: 117